BEIJING, July 9, 2025 /PRNewswire/ — Dubbed "Capital of wood carving", Dongyang in east China’s Zhejiang Province, boasts a thriving wood carving and rosewood furniture industry, bringing a staggering total revenue of 88.73 billion yuan (about 12.2 billion U.S. dollars) by the end of 2024.

As one of China’s first national-level intangible cultural heritage items, Dongyang wood carving dates back to over 1,300 years to the Tang Dynasty (618-907). Through generations of master craftsmen, Dongyang wood carving has evolved far beyond its artistic origins. The city has forged a unique and comprehensive industrial path, spanning from timber trading, product design, manufacturing and sales.

Amidst the industry’s robust growth, the local government has actively guided enterprises towards standardized, orderly, green and healthy development. Following market consolidation, the city now hosts 1,372 enterprises in the sector. This refined base includes three national high-tech enterprises and 45 enterprises above the designated size, solidifying Dongyang’s position as a key national production hub.

A robust ecosystem for talent inheritance and cultivation underpins the industry’s vitality. The city is home to over 3,000 professional woodcarving and furniture-making specialists and 18 intangible cultural heritage workshops. Furthermore, vocational institutions have established dedicated wood carving programs, continuously feeding skilled talent into the industry.

Original link: https://en.imsilkroad.com/p/346511.html

 

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

SUPCON's AI-Powered Full-stack Industrial Automation Solutions Shine at Hannover Messe 2025

HANNOVER, Germany, April 9, 2025 /PRNewswire/ — From March 31 to April…

ProLogium Shines Bright at CES 2025 with Fully Inorganic Electrolyte Battery Breakthroughs

Five transformative breakthroughs are reflected in a CES keynote titled: "Battery Breakthroughs:…

Alphamab Oncology Presented the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024

SUZHOU, China, Dec. 13, 2024 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK)…